medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2008, Number 1

<< Back

Rev Mex Patol Clin Med Lab 2008; 55 (1)

Urinary levels of endothelin-1 in type 2 diabetes mellitus patients: a non-defined marker of early renal damage

Macías-Cervantes MH, Kornhauser C, Pérez-Luque EL, Garay-Sevilla ME, Rivera-Cisneros AE

Language: Spanish
References: 30
Page: 42-47
PDF size: 103.73 Kb.


ABSTRACT

Antecedentes/Objetivo: La excreción de endotelina-1 urinaria (UET-1) es mayor en pacientes con enfermedad renal de cualquier etiología, comparados con sujetos normales, por lo que ésta podría servir potencialmente como un marcador de daño renal. Metodología: Comparamos la excreción de UET-1 en 67 pacientes con diabetes tipo 2 (DM2) con y sin hipertensión (HTA), y en presencia o ausencia de microalbuminuria (MA). Estudiamos 14 sujetos sanos como grupo control. La microalbúmina y la endotelina fueron medidas en orina de 24 horas. La diferencia entre los grupos fue determinada mediante prueba ANOVA. Utilizamos una prueba de correlación múltiple para buscar asociación entre la UET-1 y el tiempo de evolución, control metabólico y daño renal. Resultados: La excreción de UET-1 fue mayor en el grupo de diabetes sin MA con respecto al grupo de diabetes con MA (p ‹ 0.04). Se encontró diferencia significativa entre la excreción de UET-1 del grupo control y el grupo de diabetes sin HTA. Conclusiones: En nuestro estudio, la excreción de UET-1 tiende a ser mayor en pacientes diabéticos sin HTA al compararlos con pacientes diabéticos con hipertensión. Consideramos que es necesario continuar estudiando la participación de la UET-1 en la patología renal con modelos que además de evaluar la función glomerular incluyan otros sitios como el túbulo proximal.


REFERENCES

  1. Bloomgarden Z. The epidemiology of complications. Diabetes Care 2002; 25: 924-932.

  2. Sabag-Ruiz E, Alvarez-Feliz A, Celiz-Zepeda S, Gomez-Alcala AV. Chronic complications of diabetes mellitus. What is the prevalence of diabetes in a family medical unit? Rev Med Inst Mex Seguro Soc 2006; 44: 415-421.

  3. Remuzzi G, Bertanio T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.

  4. Gnudi L, Raij L. The link between Glut-1 and hypertension in diabetes nephropathy. Curr Hypertens 2006; Rep 8: 79-83.

  5. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M et al. A novel potent vasoconstrictor peptide produced by endothelial cells. Nature 1998; 332: 411-415.

  6. López-Farre A, Gómez-Garre D, Bernabeu F, Montanes I, Millas I, López-Novoa JM. Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. Kidney Int 1991; 39: 624-30.

  7. Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419-423.

  8. Denton KM, Shweta A, Finklestein L, Floerr RL, Evans RG. Effect of endothelin-1 on regional kidney blood flow and renal arteriole caliber in rabbits. Clinic Exp Pharmacol Physiol 2004; 31: 494-501.

  9. King AJ, Brenner BM. Endothelium-derived vasoactive factors and the renal vasculature. Am J Physiol 1991; 260 (4 Pt 2); R653-662.

  10. Vercellotti GM, Tolins JP. Endothelial activation and the kidney: vasomediator modulation and antioxidant strategies. Am J Kidney Dis 1993; 21: 331-343.

  11. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993; 84: 485-500.

  12. Sugimoto K, Tsuruoka S, Fujimura A. Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats. Eur J Pharmacol 2002; 450: 183-189.

  13. Rothermund L, Traupe T, Dieterich M, Kossmehl P, Yagil Ch et al. Nephroprotective effects of the ETa receptor antagonist durasten in salt sensitive genetic hypertension. Eur J Pharmacol 2003; 468: 209-216.

  14. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduce renal dysfunction in experimental diabetes. Diabetes 1998; 47: 450-456.

  15. Hynynen MM, Khalil RA. The vascular endothelin system in hypertension –recent patens and discoveries. Recent Pat Cardiovas Drug Discov 2006; 1: 95-108.

  16. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T et al. Excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39: 307-311.

  17. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17: 943-955.

  18. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002; 51: 3517-3523.

  19. Bruno CM, Meli S, Marcinno M, Ierna D, Sciacca C, Neri S. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. J Biol Regul Homeost Agents 2002; 16: 114-117.

  20. Verna LR: National Heart, Lung, and Blood Institute Releases New Guidelines for the treatment of hypertension. Am Fam Physician 1998; 57: 362-364.

  21. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920-929.

  22. American Diabetes Association: Position Statement Diabetic Nephropathy. Diabetes Care 2003; 26: s94-s98.

  23. Katsuki A, Sumida Y, Gabazza E, Murashima S, Furuta M et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-365.

  24. Shin SJ, Hsiao PJ, Hsieh MC, Lee YJ, Tsai JH. Increased urinary endothelin-1 excretion in newly diagnosed type 2 diabetic patients. Kaohsiung J Med Sic 1999; 15: 589-596.

  25. Hoffman A, Grossman E, Goldstein DS, Gill JRJ, Keiser H. Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt-sensitivity. Kidney Int 1994; 45: 556-560.

  26. Zoccali C, Leonardis D, Parlongo S, Mallamaci F, Postorino M. Urinary and plasma endothelin-1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol Dial Transplant 1995; 10: 1320-1323.

  27. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003; 81: 607-621.

  28. De Mattia G, Cassone FM, Bellin C, Bravi M, Laurenti O et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertension 1998; 11: 983-988.

  29. Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care 1994; 17: 263-266.

  30. Shin SJ, Hsiao MC, Lee YJ, Tsai JH. Increased urinary endothelin-1 excretion in newly diagnosed type 2 diabetic patients. Kaohsiung J Med Sci 1999; 15: 589-596.




2020     |     www.medigraphic.com